Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CAPSI psilocybin for cancer-related major depression
2023-505532-35-00Phase 2Authorised
- Sponsor
- Region Stockholm
- Start
- May 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of PEX010 in major depressive disorder (MDD) (2 arms), sponsored by Region Stockholm. Primary endpoints: MADRS total score at Day 42 and Time to antidepressant treatment initiation or hospitalization for depression. Planned start May 2024; status: authorised.
02
Drugs
PEX010
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on 2023-505532-35-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-505532-35-00.